Scientists test novel Two-Shot HIV vaccine in first human trial
NCT ID NCT05903339
Summary
This is a very early, first-in-human study to check if a new two-part HIV vaccine is safe and can trigger an immune response. It involves 36 healthy adults without HIV. Volunteers receive a shot of a nanoparticle-based vaccine followed later by a booster shot using mRNA technology.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS [Site ID: 31788]
Birmingham, Alabama, 35294-2170, United States
-
BIDMC VCRS [Site ID: 32077]
Boston, Massachusetts, 02215, United States
-
Brigham & Women's Hospital [Site ID: 30007]
Boston, Massachusetts, 02115, United States
-
Emory University School of Medicine, The Ponce de Leon Center CRS [Site ID: 5802]
Atlanta, Georgia, 30303, United States
-
Seattle Vaccine and Prevention CRS [Site ID: 30331]
Seattle, Washington, 98104, United States
-
Vanderbilt Vaccine (VV) CRS [Site ID: 30352]
Nashville, Tennessee, 37232-2582, United States
Conditions
Explore the condition pages connected to this study.